索元生物 is a biomedicine R&D company concentrating on the anti-tumor (oncology) field. The company introduces drugs that have been validated in clinical Phase II and III trials and that show efficacy in some patients. It applies a biomarker-platform technology to discover biomarkers and thereby optimize the safety and tolerability profiles of these therapies. The firm aims to develop innovative drugs by combining clinically validated candidates with biomarker-driven patient selection and safety optimization. Recently the company received a strategic investment of $12 million, which supports its ongoing R&D and development efforts. 索元生物 is a precision-medicine biopharma that acquires late-stage assets from major pharma and uses its proprietary biomarker platform to identify predictive biomarkers and relaunch enriched clinical trials. The company holds global rights to four late-stage, first-in-class assets (DB102, DB103, DB104, DB105). DB102 (enzastaurin) is in the global Phase 3 ENGINE trial for frontline high‑risk DLBCL (about 70% enrolled across China and the U.S.) and has an IND approved by the FDA for a global multicenter GBM Phase 2b program that is being prepared. DB103 (pomaglumetad methionil) has entered clinical testing for schizophrenia; DB105 is a selective α‑2C adrenergic antagonist for Alzheimer’s acquired from Orion; DB104 (liafensine) targets depression. After closing the B round, the company has launched a Pre‑IPO financing to support the upcoming GBM 2b study and plans to complete share reform and prepare for a Sci‑Tech Innovation Board (科创版) listing by year‑end.

Total raised

$55M

Funding rounds

2

Latest round

Equity

Latest activity

May 2024